orserdu
stemline therapeutics b.v. - elacestrant - neoplasie al seno - terapia endocrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
fulvestrant mylan
mylan pharmaceuticals limited - fulvestrant - neoplasie al seno - terapia endocrina - fulvestrant è indicato per il trattamento del recettore per gli estrogeni positivi, localmente avanzato o metastatico della mammella in donne in post-menopausa:non precedentemente trattati con terapia endocrina, ocon ricaduta di malattia o dopo coadiuvante anti-estrogeno terapia, o la progressione della malattia sulla terapia antiestrogen.
fulvestrant ever pharma
ever valinject gmbh - fulvestrant - fulvestrant
fulvestrant teva
teva italia s.r.l. - fulvestrant - fulvestrant
fulvestrant dr. reddy's
dr. reddy s s.r.l. - fulvestrant - fulvestrant
fulvestrant sun
sun pharmaceutical industries (europe) b.v. - fulvestrant - fulvestrant
fulvestrant accord
accord healthcare, s.l.u. - fulvestrant - fulvestrant
fulvestrant eg
eg s.p.a. - fulvestrant - fulvestrant
fulvestrant eg stada
eg s.p.a. - fulvestrant - fulvestrant
fulvestrant sandoz
sandoz s.p.a. - fulvestrant - fulvestrant